Before the Inflation Reduction Act, Medicare Part D had no annual ceiling on what an enrollee paid for covered drugs. A beneficiary on a specialty biologic could spend $8,000 or more in true out-of-pocket costs in a single plan year and still be paying a 5 percent coinsurance in December. Starting January 1, 2025, that changed. The IRA established a $2,000 per-year out-of-pocket capon Part D drug costs, the first hard limit in the program's 20-year history. For brokers doing AEP consultations with clients on high-cost medications, this is not a footnote. It changes the entire math of plan comparison.
Key Takeaways
- The Inflation Reduction Act capped Medicare Part D out-of-pocket drug costs at $2,000 per year starting in 2025. Before 2025, there was no annual OOP cap: catastrophic-phase spending could continue indefinitely.
- The $590 initial deductible for 2025 still applies. The $2,000 cap counts spending beyond that deductible and includes the old coverage gap phase, which no longer exists as a separate structure.
- Low-income subsidy (Extra Help / LIS) enrollees had their own reduced cost-sharing before 2025. The $2,000 cap changes their math less than it changes the math for standard-benefit enrollees.
- The Medicare Prescription Payment Plan (M3P) is a new opt-in program that lets enrollees spread their OOP costs into equal monthly installments across the plan year instead of paying everything upfront in January and February.
- The $2,000 cap is indexed to Part D expenditure growth each year after 2025, so it will not stay at exactly $2,000 long-term.
What the old structure looked like and what replaced it
From 2006 through 2024, Part D operated on a four-phase structure: initial deductible, initial coverage period, coverage gap, and catastrophic coverage. The coverage gap, commonly called the donut hole, was the phase in which enrollees paid a flat percentage of drug costs after their coverage reached a spending threshold. By 2024, the ACA had already reduced coverage gap cost-sharing to 25 percent, but there was still no ceiling beyond the catastrophic phase, which itself only reduced the enrollee's cost to 5 percent of drug costs.
The IRA collapsed that four-phase structure into a simpler two-phase structure for 2025. Enrollees pay the initial deductible and then pay cost-sharing (copay or coinsurance per plan formulary) until their true out-of-pocket spending reaches $2,000. After that point, the plan pays 100 percent of covered drug costs for the remainder of the plan year.
| Phase | Before 2025 | 2025 and after |
|---|---|---|
| Initial deductible | $545 for 2024 — enrollee pays 100% of drug costs until deductible is met | $590 for 2025 — structure unchanged |
| Initial coverage period | Enrollee pays copay or coinsurance; plan pays rest until TrOOP hits coverage gap threshold | Same cost-sharing structure; no separate coverage gap threshold applies |
| Coverage gap (donut hole) | 25% coinsurance on brand-name and generic drugs after entering the gap | Eliminated as a separate phase. Spending continues to accumulate toward $2,000 OOP cap |
| Catastrophic coverage | After $8,000 TrOOP: enrollee paid 5% (or a small copay) with no annual cap | Eliminated. After $2,000 OOP: plan pays 100% of covered drug costs for the rest of the plan year |
Illustrative comparison. Actual deductibles, thresholds, and cost-sharing depend on plan year and CMS final rule.
What counts toward the $2,000 cap and what does not
The cap applies to true out-of-pocket spending, which the program tracks through a metric called TrOOP. TrOOP counts what the enrollee actually pays: deductible, copays, and coinsurance on covered Part D drugs. It does not count premiums. A client paying $60 per month in Part D premiums has $720 in annual premium expense that runs entirely outside the $2,000 cap.
Manufacturer discounts on brand-name drugs count toward TrOOP under the IRA structure. Before 2025, manufacturer gap discounts did not count toward TrOOP in the coverage gap phase, which meant enrollees reached the catastrophic threshold faster but were not actually paying that full amount themselves. The IRA alignment means that the TrOOP accumulation matches what the client's wallet experiences more accurately than before.
Non-formulary drugs and drugs purchased outside the plan's network do not count toward TrOOP. A client who pays cash for a drug at a retail pharmacy without using the Part D plan does not get credit for that purchase toward the $2,000 cap. This is a nuance that comes up with clients who use GoodRx or similar discount programs for some medications while running other drugs through Part D.
The Medicare Prescription Payment Plan: spreading costs across the year
The IRA also created the Medicare Prescription Payment Plan (M3P), an opt-in mechanism that lets enrollees spread their annual OOP drug costs into equal monthly installments. Rather than paying a $400 copay for a specialty drug in January, the enrollee pays roughly one-twelfth of their estimated annual OOP exposure each month.
The total amount paid does not change under M3P. The plan year OOP cost is the same; M3P only changes the timing. Plans can default-enroll beneficiaries into M3P with an opt-out option, or they can make it purely opt-in. CMS guidance from 2024 allows plans flexibility in the enrollment mechanism.
The clients for whom M3P matters most are those who hit large specialty drug costs in the first two months of the plan year. A beneficiary on a $12,000-per-year biologic might hit the $2,000 OOP cap by late February under the standard payment structure, creating significant cash-flow pressure in January. M3P converts that $2,000 into twelve roughly $167 monthly payments, which is often more manageable on a fixed income.
How this changes the math for LIS (Extra Help) enrollees
Low-income subsidy enrollees already had substantially reduced cost-sharing well before the IRA. Full LIS recipients in 2025 pay a $0 deductible, fixed copays of $4.50 for generics and $11.20 for brand-name drugs (with an annual cap well below $2,000). Partial LIS recipients have a reduced deductible and reduced cost-sharing.
For full LIS enrollees, the $2,000 cap rarely comes into play because their total annual drug cost-sharing is already below that threshold for most formularies. The IRA changes affect them less than they affect standard-benefit enrollees who previously had to navigate the coverage gap and catastrophic phase on their own.
Where LIS enrollees do benefit is from the manufacturer discount alignment in TrOOP: their coverage is now structured in a way that more accurately reflects their actual spending. But the headline $2,000 cap story is primarily for standard-benefit enrollees on high-cost drugs. Brokers should calibrate the AEP conversation accordingly.
For context on how IRMAA income surcharges interact with Part D costs, see the post on Medicare Part B and Part D IRMAA explained. For the enrollment window context, see the overview of AEP vs OEP vs Medicare Advantage SEP.
What changes in the AEP conversation for 2026 plan year
The plan selection question for clients on expensive medications shifted with the IRA. Before 2025, some clients chose lower-premium PDPs and accepted higher cost-sharing because they knew they'd reach catastrophic status quickly and then pay only 5 percent. The $2,000 OOP cap changes that calculus: a lower-premium plan may now put the client at risk for higher cost-sharing before the cap, while a higher-premium Enhanced plan may reduce cost-sharing enough to offset the premium difference.
The actual breakeven depends on the specific drugs, the formulary tier, and the cost-sharing structure of the plans being compared. Quotit and other Medicare quoting tools allow formulary-level plan comparison, but the IRA benefit modeling is a relatively new feature and not all platforms surface it consistently.
The practical first step for any client on a specialty drug: ask them how much they paid for their highest-cost medication in 2024. If the answer is over $2,000 in drug cost-sharing alone, the conversation about IRA benefits is straightforward. If the answer is under $2,000, the cap may not change their annual spend at all, and the plan-selection conversation stays focused on formulary coverage and premium.
Also ask about cash-flow. A client who understands they will hit the $2,000 cap by March but struggles with large early-year copays is a candidate for the M3P conversation, regardless of whether the cap changes their total annual cost.
Medicare Part D and the IRA $2,000 cap: broker questions
The structural change to Part D creates questions that clients rarely ask in the abstract but consistently ask when reviewing their EOBs.
Does the $2,000 Part D OOP cap include premiums?
No. The $2,000 cap applies only to cost-sharing: deductible, copays, and coinsurance for covered Part D drugs. Monthly premiums are not counted toward the cap. This distinction matters for clients who pay high Part D premiums for Enhanced plans with richer formularies. They still have premium exposure above the $2,000 cap on their drug cost-sharing.
What happened to the donut hole after the Inflation Reduction Act?
The coverage gap, also called the donut hole, was a phase in which enrollees paid 25 percent of drug costs after the initial benefit phase ended. Under IRA, that structure was eliminated for 2025. The prior three-phase design (initial benefit, coverage gap, catastrophic) collapsed into a simpler two-phase structure: initial deductible plus cost-sharing, then the $2,000 OOP cap after which the plan pays 100 percent. Manufacturer price discounts that previously flowed to the coverage gap now help offset spending earlier in the year.
How does the Medicare Prescription Payment Plan work in practice?
The M3P lets an enrollee elect to spread their estimated annual OOP drug costs into roughly equal monthly payments. Instead of paying a $400 copay in January for a specialty drug, the enrollee pays a prorated monthly amount across the plan year. Plans are required to offer the M3P option; beneficiaries opt in, or plans can default-enroll them with opt-out. The net cost-sharing amount does not change but the timing does, which helps clients on fixed incomes avoid large early-year bills.
Does the $2,000 cap reset each plan year?
Yes. The out-of-pocket cap resets on January 1 of each plan year. Costs from one plan year do not carry into the next, regardless of how close the enrollee was to the cap in December. This is the same structure as most private health insurance OOP maximums. A client who hits $1,900 in OOP costs in December starts from zero on January 1.
How should brokers explain the IRA Part D changes during AEP conversations?
The core message for most clients: there is now a ceiling on what they pay for covered drugs in a plan year, and that ceiling is $2,000. Clients who take expensive specialty drugs benefit most, because they previously had no cap after the catastrophic threshold was crossed. Clients who use only generic drugs may have already been spending under $2,000 per year, so the cap does not change their actual outlay. For high-cost drug users, the M3P option deserves a specific conversation about cash-flow management.
